Wall Street Analysts See a 50.01% Upside in Nektar (NKTR): Can the Stock Really Move This High?Zacks Investment Research • 10/28/25
Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific MeetingPRNewsWire • 10/22/25
This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall StreetThe Motley Fool • 10/13/25
These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?The Motley Fool • 09/21/25
Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025PRNewsWire • 09/18/25
Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025PRNewsWire • 09/09/25
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/07/25
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial MarketsPRNewsWire • 07/31/25
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia AreataPRNewsWire • 07/29/25
Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesPRNewsWire • 07/02/25